Introduction
============

Circulating markers of inflammation may predict cardiovascular risk. Lipoprotein-associated phospholipase A~2~ (Lp-PLA~2~) is a macrophage-derived enzyme from the phospholipase A~2~ superfamily that has been shown to be an independent predictor of cardiovascular disease (CVD) and future events. Several epidemiological and clinical studies have examined the role of Lp-PLA~2~ in CVD, and in the aggregate, the evidence suggests a role for the use of this biomarker in risk prediction.

The role of Lp-PLA~2~ in atherosclerosis
========================================

Lipoprotein-associated phospholipase A~2~, also known as platelet activating factor acetylhydrolase (PAF-AH), is a 50 kD Ca^2+^-independent phospholipase, distinct from another macrophage product, secretory PLA2, a 14kD Ca^2+^-dependent enzyme ([@b6]). Lp-PLA~2~ is expressed in atherosclerotic plaques ([@b7]), and in macrophages within the fibrous cap of human rupture prone lesions ([@b11]). Lp-PLA~2~ is transported in plasma predominantly associated with low density lipoprotein (LDL) ([@b5]). Lp-PLA~2~ causes hydrolysis of modified phospholipids within oxidized LDL (OxLDL), generated by LDL oxidation in the milieu of the artery wall ([@b13]; [@b18]; [@b14]), resulting in the production of lysophosphatidylcholine (LysoPC) and oxidized fatty acids (OxFA) ([@b13]). The proinflammatory and atherogenic properties of LysoPC are well known ([@b17]; [@b13]).

Lp-PLA~2~ modulation by pharmacological interventions
-----------------------------------------------------

Preclinical studies have shown that inhibition of Lp-PLA~2~ significantly reduces atherogenesis ([@b14]). Initial clinical studies suggest that the inhibitors of Lp-PLA~2~ can block enzyme activity in plasma and within atherosclerotic plaques ([@b12]). Statins and fibrates are known to decrease cardiovascular events and reduce plasma Lp-PLA~2~ levels ([@b22]; [@b19]). There appears to be differences among the statins, with atorvastatin being more effective than fluvastatin, lovastatin, pravastatin, or simvastatin for decreasing not just LDL-cholesterol, but also high sensitive C-reactive protein (hs-CRP) (32% reduction with atorvastatin) and Lp-PLA~2~ (26% reduction with atorvastatin) ([@b19]).

Assessment of Lp-PLA~2~ Levels
------------------------------

Lp-PLA~2~ mass is measured by an enzyme immunoassay in human plasma (the PLAC™ test) ([@b6]). In addition, Lp-PLA~2~ activity can also be measured in human plasma ([@b21]).

Cardiovascular risk prediction in clinical studies
==================================================

WOSCOPS (The West of Scotland Coronary Prevention Study) was a primary prevention trial designed to evaluate the use of pravastatin in hypercholesterolemic men ([@b16]) ([Table 1](#tbl1){ref-type="table"}). A 2-fold greater risk of coronary heart disease (CHD) was observed for patients in the highest quintile of Lp-PLA~2~ levels compared with those in the lowest quintile. Similar to Lp-PLA~2~, the risk of CHD was 2-fold greater in the highest quintile of CRP levels and white-cell count compared with the lowest quintile. However, on multivariate analysis, risk associated with CRP levels and white-cell counts was attenuated, but the association of Lp-PLA~2~ with risk of CHD remained significant for all quintiles (p=0.005), demonstrating the strength of Lp-PLA~2~ as an independent marker of CHD. Of note, Lp-PLA~2~ was the only marker of inflammation whose levels were not affected by smoking.

###### 

Studies and trials demonstrating significant independent association between Lp-PLA~2~ levels and cardiovascular endpoints, expressed either as HR (highest compared with lowest tertile, quartile, or quintile) or RR per 1 SD

  Author        Population                     Endpoints                Risk
  ------------- ------------------------------ ------------------------ -----------------
                                                                        **HR**
  Ballantyne    ARIC:Healthy subjects          Coronary events          2.08 (LDL\<130)
  Ballantyne    ARIC:Healthy subjects          Stroke                   1.97
  Khusiyenova   Southern Germans:CAD           Presence of CAD          1.84
  Oei           Rotterdam:Elderly              Coronary events/stroke   1.96/1.95
                                                                        **RR per 1 SD**
  Packard       WOSCOPS:Hypercholesterolemia   Cardiac events           1.18
  Brilakis      Mayo Clinic study:CAD          Cardiac events           1.27
  Iribarren     CARDIA:Youngadults             Coronary calcification   1.25
  Koenig        MONICA:Healthy men             Coronary events          1.21

**Abbreviations:** ARIC, Atherosclerosis Risk in Communities; CAD, coronary artery disease; CARDIA, Coronary Artery Risk Development in Young Adults; HR, hazard ratio; LDL, low-density lipoprotein; MONICA, Monitoring Trends and Determinants in Cardiovascular Diseases; RR, risk ratio; SD, standard deviation; WOSCOPS, West of Scotland Coronary Prevention Study.

The ARIC study (Atherosclerosis Risk in Communities) ([@b1]) was a prospective study designed to evaluate atherosclerosis over a period of 6 years in over 12 000 apparently healthy middle-aged men and women. In a case-cohort analysis, a hazard ratio (HR) of 1.78 (95% confidence index \[CI\], 1.33--2.38) for the highest tertile of Lp-PLA~2~ (≥422 μg/L) and HR 2.53 (1.88 to 3.40) for the highest tertile of CRP (\>3.0 mg/L) was reported. In patients with LDL levels below the median (\<130mg/dL), both Lp-PLA~2~ and CRP levels were significantly and independently associated with CHD, even in fully adjusted models. Those individuals with increased levels of both Lp-PLA~2~ and CRP were found to have the greatest risk for a CHD event (HR 2.95 CI, 1.47--5.94\]).

In a Southern German study examining subjects from the MONICA (Monitoring Trends and Determinants in Cardiovascular Diseases) population, the relationship between Lp-PLA~2~ levels and risk of coronary events was evaluated in 934 healthy men aged 45 to 64 years who were followed for 14 years ([@b10]). In the 97 men who suffered a coronary event, mean baseline levels of Lp-PLA~2~ were significantly higher in men who had suffered an event. A 1 standard deviation (SD) increase in Lp-PLA~2~ mass was associated with a 37% increase in risk of future coronary events, even after controlling for potentially confounding factors and CRP. The combination of a high Lp-PLA~2~ (\>290.8 μg/L) and a high CRP (\>3 mg/L) was consistently associated with a statistically significantly increased risk for future coronary events, suggesting that these biomarkers may be complementary in identifying high-risk subjects.

The Rotterdam Study was a population-based follow-up study in 7983 subjects aged 55 years and over. [@b15] performed a case-cohort study, including 308 CHD cases, and a random sample of 1820 subjects. Compared with the first quartile of Lp-PLA~2~ activity, multivariate-adjusted HRs for CHD for the second, third, and fourth quartiles were 1.39 (95% CI, 0.92 to 2.10), 1.99 (95% CI, 1.32 to 3.00), and 1.97 (95% CI, 1.28 to 3.02), respectively (p for trend=0.01). The Rotterdam study thus provides additional evidence for an association between Lp-PLA~2~ and CHD, independent of other risk factors.

One small study ([@b3]) failed to show an independent association between Lp-PLA~2~ levels and risk of CHD. In univariate analysis, mean levels of Lp-PLA~2~ were significantly higher at baseline among cases than controls, but the predictive value of Lp-PLA~2~ was attenuated after adjustment for other cardiovascular risk factors. This study examined a small number of women, many of whom were on hormonal therapy, which may explain the disparate observations in this study compared with others showing a relationship between Lp-PLA~2~ levels and risk of CHD.

Studies of Lp-PLA~2~ in patients with angiographic evidence of coronary artery disease
--------------------------------------------------------------------------------------

In a study of 148 men, 48 with angiographically proven coronary artery disease (CAD), 46 who had suffered myocardial infarction at least 1 year prior to the study, and 54 normal aged-matched controls ([@b5]), elevated levels of Lp-PLA~2~ were found in patients with angiographic CAD compared with the normal patients, independent of LDL and other risk factors including smoking and systolic blood pressure. Another study ([@b9]) in German patients with angiographic evidence of CAD and in age- and gender-matched blood donors confirmed that Lp-PLA~2~ concentrations were significantly higher in cases than in controls; further age and gender adjusted odds ratio (OR) for the presence of CAD was 1.61 (95% CI, 1.07--2.44) when the top quartile of the Lp-PLA~2~ distribution was compared with the bottom quartile. Adjustment for traditional cardiovascular risk factors and statin intake resulted in an OR of 2.04 (1.19--3.48). An additional study ([@b4]) in 504 patients at the Mayo Clinic undergoing clinically indicated coronary angiography, demonstrated higher Lp-PLA~2~ levels were associated with a greater risk of events: the HR per SD was 1.28 (95% CI, 1.06--1.54, p=0.009), and remained significant after adjusting for clinical and lipid variables and CRP.

Lp-PLA~2~ in young adults with coronary artery calcification
------------------------------------------------------------

The association between Lp-PLA~2~ (mass and activity), and coronary artery calcification (CAC) in young adults was examined in a nested case-control study using data from the Coronary Artery Risk Development in Young Adults (CARDIA) study ([@b8]). Lp-PLA~2~ mass and activity were significantly higher in cases than in controls. The OR of calcified coronary plaque per 1 SD increment was 1.40 (1.17 to 1.67) and 1.39 (1.14 to 1.70) for Lp-PLA~2~ mass and activity, respectively; the relationship was independent of LDL-cholesterol. After adjusting for multiple covariates, a statistically significant association remained for Lp-PLA~2~ mass (1.28; 95% CI, 1.03--1.60) but not for activity. Thus, Lp-PLA~2~ (measured as mass) appears to be involved in early CAC.

Lp-PLA~2~ as a risk predictor for stroke
----------------------------------------

Recently, [@b15] compared 110 ischemic stroke cases with a random sample of 1820 subjects in a case-cohort analysis in the Rotterdam study, and also reported a significant association between Lp-PLA~2~ activity and ischemic stroke. Compared with the first quartile of Lp-PLA~2~ activity, multivariate-adjusted HRs for ischemic stroke were 1.08 (95% CI, 0.55 to 2.11), 1.58 (95% CI, 0.82 to 3.04), and 1.97 (95% CI, 1.03 to 3.79) (p for trend=0.03). In a further analysis from the ARIC study, the relation between Lp-PLA~2~, CRP, traditional risk factor (RFs), and stroke over 6 years was examined ([@b2]). Both Lp-PLA~2~ and CRP were associated with stroke after adjustment for age, sex, and race with a HR of 2.16 for the highest versus the lowest tertile of Lp-PLA~2~ and 2.64 for CRP. In a model including CRP and Lp-PLA~2~ with traditional RFs plus body mass index (BMI), triglycerides, and antihypertensive medication, the highest tertile of Lp-PLA~2~ had an HR of 2.04 (1.23--3.38, p\<0.01). Individuals with high levels of both CRP and Lp-PLA~2~ were at the highest risk after adjusting for traditional risk factors.

Thus, both Lp-PLA~2~ and CRP may be complementary beyond traditional risk factors in identifying individuals at increased risk for stroke. Inflammation may play a role in the etiology of stroke, reflected at least in some patients by elevated levels of inflammatory biomarkers, and antiinflammatory properties of statins may be crucial to their beneficial effects on stroke reduction.

Conclusions
===========

Lp-PLA~2~ plays a critical role in atherogenesis, and may indeed be a marker of inflammation ([@b20]). Inhibition of Lp-PLA~2~ may have antiatherogenic effects. Studies from the WOSCOPS and MONICA cohorts have shown that the association of Lp-PLA~2~ with CHD is not attenuated upon multivariate analysis with other inflammatory markers and traditional risk factors. Two recent studies have shown that Lp-PLA~2~ is a predictor of stroke risk. Measurement of Lp-PLA~2~ in plasma may be useful in identifying subjects at high risk for future cardiovascular events.
